PepGen Inc. (NASDAQ:PEPG) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC raised its stake in PepGen Inc. (NASDAQ:PEPG - Free Report) by 331.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,336,516 shares of the company's stock after purchasing an additional 1,794,641 shares during the period. Janus Henderson Group PLC owned about 7.17% of PepGen worth $20,012,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in PEPG. Suvretta Capital Management LLC increased its holdings in PepGen by 9.2% in the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company's stock valued at $14,201,000 after buying an additional 140,000 shares during the last quarter. Vanguard Group Inc. raised its position in shares of PepGen by 68.0% during the 1st quarter. Vanguard Group Inc. now owns 850,445 shares of the company's stock worth $12,502,000 after acquiring an additional 344,266 shares in the last quarter. Sofinnova Investments Inc. lifted its stake in PepGen by 11.4% during the second quarter. Sofinnova Investments Inc. now owns 561,128 shares of the company's stock worth $8,956,000 after purchasing an additional 57,504 shares during the last quarter. Walleye Capital LLC purchased a new stake in PepGen during the third quarter worth approximately $519,000. Finally, Bank of New York Mellon Corp increased its stake in PepGen by 43.6% in the second quarter. Bank of New York Mellon Corp now owns 44,157 shares of the company's stock valued at $705,000 after purchasing an additional 13,397 shares during the last quarter. Hedge funds and other institutional investors own 58.01% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PEPG. Wedbush reduced their price target on shares of PepGen from $19.00 to $12.00 and set an "outperform" rating for the company in a research report on Friday, November 8th. Bank of America decreased their target price on PepGen from $10.00 to $6.00 and set a "neutral" rating for the company in a research report on Monday, November 18th. Finally, HC Wainwright restated a "buy" rating and set a $26.00 price target on shares of PepGen in a research note on Friday, November 8th.

PepGen Stock Up 1.4 %

NASDAQ PEPG traded up $0.08 during trading hours on Friday, hitting $5.71. 322,730 shares of the stock were exchanged, compared to its average volume of 171,894. PepGen Inc. has a 12-month low of $4.00 and a 12-month high of $19.30. The stock has a 50-day moving average of $6.85 and a 200 day moving average of $11.02. The company has a market cap of $186.15 million, a price-to-earnings ratio of -1.92 and a beta of 1.56.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.